Cagrisema
3 papers3 findings
- 1 lab
- 9 trials
- 1 of 9 trials sponsored by its developers
- Humans1
Outcomes
3Creatinine
downin humans1
1 study
Creatinine
downin humans1
Cagrisema decreases creatinine in humans (-17.4% vs -2.4%, BH P=0.020).
“creatinine (-17.4% vs -2.4%, BH P=0.020), and greater increases in eGFR (+26.4% vs +6.4%, BH P=0.030)”
Humanscompared with matched empagliflozin-treated patients6 months
Preprints.org3 Sep 2026Preprint
Mean arterial pressure
downin humans1
1 study
Mean arterial pressure
downin humans1
Cagrisema decreases mean arterial pressure in humans (-12.0% vs -1.0%, BH P<0.001).
“larger reductions in weight (-7.7% vs -3.5%, P=0.048), mean arterial pressure (-12.0% vs -1.0%, BH P<0.001)”
Humanscompared with matched empagliflozin-treated patients6 months
Preprints.org3 Sep 2026Preprint
Estimated glomerular filtration rate
upin humans1
1 study
Estimated glomerular filtration rate
upin humans1
Cagrisema increases estimated glomerular filtration rate in humans (+26.4% vs +6.5%, BH P=0.028).
“larger increases in estimated glomerular filtration rate (+26.4% vs +6.5%, BH P=0.028)”
Humanscompared with matched tirzepatide-treated patients6 months
Preprints.org3 Sep 2026Preprint
Trials
9In trials
Phase 3Active, not recruiting4 trials
Phase 3Recruiting4 trials
Trial sponsors
Company1 trialPhase 32,500 people